Peter Evan Harwin
Independent DirectorMr. Peter Evan Harwin serves as Founding Partner and Managing Member at Fairmount Funds Management LLC, which he co-founded in April 2016. He serves as Director of Alaunos Therapeutics, Inc. since October 13, 2026. At Damora Therapeutics, Inc. (formerly known as Galecto, Inc.), he serves as Independent Chairman of the Board since March 2026, and also served as Independent Director from November 10, 2025 to March 2026. At Crescent Biopharma, Inc., he serves as Independent Chairman and also served as its Independent Director from September 2024. At Cogent Biosciences, Inc. (formerly known as Unum Therapeutics Inc.), he serves as Independent Chairman of the Board and also served as an Independent Director of the company from July 6, 2020. Mr. Harwin serves as Independent Director of Oruka Therapeutics, Inc. since February 2024. He serves as a Director of Paragon Therapeutics, Inc. He serves as strategic advisor to Dianthus Therapeutics, Inc. and Quellis Biosciences Inc., where he also served as Director. His prior experience includes serving as Independent Director at Spyre Therapeutics, Inc. (formerly known as Aeglea BioTherapeutics, Inc.) from June 2023 to May 27, 2026. He served as Independent Chair from June 2023 and as an Independent Director at Apogee Therapeutics, Inc., with his tenure at the company ending on May 11, 2026. He also served as a Member of the Board of Apogee Therapeutics, LLC from 2022 until May 11, 2026. Mr. Harwin served as an Independent Director at Viridian Therapeutics, Inc. from October 2020 to March 10, 2025. He served as Director of Unum Therapeutics Inc. from July 6, 2020. He also served as Director of Mentari Therapeutics, Inc. Prior to Fairmount, he served for several years as a Member of the investment team at Boxer Capital, LLC. He received his Bachelor of Business Administration in Finance from Emory University from 2004 to 2008.
Positions
- Company NameOruka Therapeutics, Inc.Stock CodeORKAPositionIndependent DirectorColleagues
- LOLawrence Otto KleinPresident, CEO & Director
- SKSamarth KulkarniIndependent Chairman of Board
- PTPaul T. QuinlanGeneral Counsel & Secretary
- JGJoana GoncalvesChief Medical Officer
- AAArjun AgarwalSenior VP of Finance & Treasurer
- LSLaura SandlerChief Operating Officer
- KMKristine M. BallIndependent Director
- PEPeter Evan HarwinIndependent Director
- ABAndrew BlauveltChairman of Scientific Advisory Board
- Company NameCrescent Biopharma, Inc.Stock CodeCBIOPositionIndependent ChairmanColleagues
- JTJoshua T. BrummCEO & Director
- PEPeter Evan HarwinIndependent Chairman
- JMJonathan McNeillPresident & COO
- EIEllie ImChief Medical Officer
- RWRichard William ScalzoChief Financial Officer
- RLRyan LynchSenior VP of Finance, Treasurer & Chief Accounting Officer
- ABAlexandra BalcomIndependent Director
- DCDavid Charles LubnerIndependent Director
- JVJonathan ViolinDirector
- Company NameDamora Therapeutics, Inc.Stock CodeDMRAPositionIndependent Chairman of the BoardColleagues
- GWGarrett WinslowSenior VP, General Counsel & Corporate Secretary
- PEPeter Evan HarwinIndependent Chairman of the Board
- JAJennifer A. JarrettCEO, President & Director
- UJUlf J. NilssonCo-Founder
- HLHakon LefflerCo-Founder
- TSTariq SethiCo-Founder
- CWChristopher W. CainIndependent Director
- MLMichael LandsittelIndependent Director
- JFJonathan FallowfieldMember of Clinical Advisory Board – Liver cirrhosis
- Company NameCogent Biosciences, Inc.Stock CodeCOGTPositionIndependent Chairman of the BoardColleagues
- ARAndrew R. RobbinsPresident, CEO & Director
- JLJohn L. GreenCFO & Principal Accounting Officer
- JEJohn Edward RobinsonChief Scientific Officer
- JSJessica SachsChief Medical Officer
- CPCole PinnowChief Commercial Officer
- KJKaren Jean FerranteIndependent Director
- AMArlene M. MorrisIndependent Director
- TETodd E. ShegogIndependent Director
